Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patrick,
Did you get into Etrm after the last drop in sp?
Gary, do you think that could be holding the sp down a little?
New video out of Horst on Fox Business News
http://video.foxbusiness.com/v/4163821880001/new-drug-tablet-versafilm-gets-rid-of-migraines-in-30-seconds/?#sp=show-clips
IntelGenx Technologies Finally Finds Its Stride (AMGN, IGXT, GSK)
Amgen, Inc. (NASDAQ:AMGN) and GlaxoSmithKline plc (NYSE:GSK) aren't immediately threatened by IntelGenx Technologies Corp. (OTCMKTS:IGXT), but that doesn't mean IGXT can't offer a reward to its shareholders.
By James E. Brumley
Dec 1, 2014 9:11:42 AM PST | 43 View(s) | No Comment(s) - Post a Comment Rating
When one thinks of a biopharma conglomerate, usually names like Amgen, Inc. (NASDAQ:AMGN) or GlaxoSmithKline plc (NYSE:GSK) come to mind. And for good reason. GlaxoSmithKline has generated revenue of $37.3 billion over the past twelve months, while Amgen has generated $19.7 billion worth of sales over its prior four quarters. Size, however, isn't a prerequisite for success in the world of biotech, though. Neither is a huge array of product offerings. Opportunity is all relative, which is what makes IntelGenx Technologies Corp. (OTCMKTS:IGXT) such an interesting opportunity for investors right now.
With a mere market cap of $40 million, it's not as if IGXT garners a lot of media attention. It's that current lack of attention that makes the stock so juicy here, however - the likely "bid up" once the organization is discovered (in earnest) has yet to materialize. Such an even may be closer than most suspect, though.
IntelGenx Technologies is as much a platform developer as it is a drug developer. The company has created three drug-development platforms... an immediate release oral film called VersaFilm(tm), a mucoadhesive tablet names AdVersa(tm), and a multilayer controlled release tablet, VersaTab(tm). Partners are already on board using these technologies to design new drugs, but more are being sought.
In the meantime, IGXT has an attractive pipeline of its own in addition to a small but growing stable of approved drugs.
Its flagship and only on-the-market drug this far is Forfivo, as a therapy for major depressive disorder. It's a competitive market to be sure, with drugs like Lexapro, Celexa, and Paxil - and all their generic versions - maintaining a pretty tight grip on their market share. Forfivo is chipping away pretty impressively, though. in the third quarter of this year, IGXT drove $450,000 in sales. No, it's not a lot on the surface, but compared to Q3-2013's (before Forfivo was approved) top line of $100,0000 and Q2's revenue of $160,000, it's clear sales the company's depression drug is picking up speed.
Other drugs are moving onto the menu too. Rizaport, for migraines, is now being reviewed by European regulators. Two more specific drugs are pretty well through the pipeline as well, waiting for partners, and several more drugs are on the development table.
Said another way, there's never been more going for the company before than there is now, even though the stock's price has been much higher in the past than in is now.
None of that, however, is really what makes IGXT a prime trading candidate right now. Right now, this stock is a buy mostly because the downtrend that beat the stock to a pulp since early February has been snapped, and the bulls are charging. Shares have rallied from a low of 33 cents to their current price of 61 cents in just a little over a month, on strong volume. The bulls don't appear to be done yet, either.
Bottom line? It's one of those stories you often don't hear about it until well after the fact. This isn't to say IntelGenx Technologies Corp. is the next Amgen or the next GlaxoSmithKline plc, because it probably isn't... and certainly won't be for years. On the flipside, all large companies started out small, one way or another. Between three marketable drug development platforms, one approved drug, one partner-developed drug under review in Europe, and a handful more ready to push deeper into the pipeline, this stock could make for in interesting addition to the aggressive portion of portfolios.
www.smallcapnetwork.com
Significant growth in revenues expected for IntelGenx, says H.C. Wainwright
Thursday, December 4th, 2014
IntelGenx Technologies (OTCMKTS:IGXT) (CVE:IGX), a company focused on orally adminstered drug products, had its buy rating and $2.00 price target reiterated by H.C. Wainwright Thursday, with the brokerage anticipating significant growth in revenues beyond 2016.
In a business update yesterday, management emphasized its confidence in partner Edgemont in maximizing Forfivo XL (a drug to treat depression) commercialization efforts, analyst Swayampakula Ramakanth said.
“This is underscored by Edgemont extending its license to exclusively market the product until the entry of an authorized generic in January 2018.
“Management is anticipating a seven-figure payment associated with license extension that will be accounted over the next two quarters (4Q14 and 1Q15). IntelGenx also believes that in early 2015 Edgemont’s efforts could aid in Forfivo XL cross a sales threshold, which would trigger a pre-determined milestone payment that the company would receive during late 2015,” H.C. Wainwright said.
“With the infusion of these milestone revenues, we expect the company to attain operating profitability by the end of 2015, earlier than our previous expectation of 2016.”
In addition, the analyst noted that Edgemont increased its sales efforts to sell Forfivo XL, and is currently employing 10 sales personnel, versus none at the end of 2013. During this period, monthly scripts for the drug rose to 1,700 to 2,700 as of October. If the current growth trend continues, H.C. Wainwright anticipates scripts to exit 2014 at nearly 3,100.
The company also has a migraine drug undergoing a a marketing application review by the German Federal Institute for Drugs and Medical Devices, with a potential European launch happening as early as the beginning of 2016. It could also enter the US market in early 2016.
On top of this, the brokerage noted a successful preclinical study of INT0036, a schizophrenia drug, with a pilot phase 2 study planned for the first half of next year, which if successful, could potentially result in a partnership to commercialize the product.
IntelGenx could also benefit from plans to initiate construction of a manufacturing plant next year, which could lower some of the risks in maufacturing and improve cost efficiency of development programs, H.C. Wainwright said.
How long are you going to hold out before you rebuy? Are you looking for a certain price for it to get to or for the company to get to a certain point developmentally? Just curious.
Gary, Now is the time to be long on this stock! We sat through the all the crap and now the good times are coming and you're out? You're going to miss the boat.
New September presentation.
It can be found on twitter but it doesn't come up on their website. I think it's been mentioned before but the one on the page is still the June presentation.
http://www.slideshare.net/ViralNetwork/intelgenx-corporate-presentation-2012
Hey Gary,
Did you see that Intelgenx is now list on Par's website as a partner? I knew Par was always on Intelgenx's website but never the other way around. I take that as good news. Re-entered this week at .69
I think it will be tested again today
thanks gary. I will continue to follow the stock but maybe lay low for a little while. good luck to you as well!
bought at .58 sold at .985/1.00. bought in my second time at .915 sold out at .98(yesterday late) and .94 this morning for a slight gain. i hate having to trade this stock because it has so much going for it but i am here to make money. looking to get back in at the low 70's. good luck to all
holding 15,000 shares
Bought back in 21000 at .915. Hope this was a good move. Too much potential!
LOL. So I've heard!
Thanks Gary. I followed you guys for awhile on here and it's about damn time we made some money. What is your opinion on an reentry point?
Thank you. After all, we are here to make some money! I was able to unload 12,000 out of 12,025 shares. Not too bad. Looking to possibly reenter half at a lesser price. What do you think as a reentry point?
Indeed it is. I just posted the remaining 12,025 @ .985. If it sells, I would be looking at a 57.88% gain according to etrade.
sold 7,650 at 1.00 today, bought at .521. Nice gain, I will take it!
Holding 19,675 shares at .5826. Need to figure out what i'm going to real quick.
I think maybe a new presentation is coming soon. I was on the Intelgenx website and I can't get the next slide to come up. Hopefully they are updating it with some great news.
no sweat Gary. you bring a lot to the table on this board. I might not say much but I try and follow what's going on. thanks for your input
.56 that's U.S., .60 Canadian
Updated presentation on Intelgenx website
Intelgenx copartner for antimigraine film, red hill biopharma, gets Nasdaq listing. More exposure. We're getting there, slowly.
Im in for 30k at about .67, most shares over a year. Definately ready for a move up but im not going anywhere anytime soon. I want to see this playout
etrade isn't recording trading correctly either.
I wonder if it's a new drug or if it is going to be the technology applied to their drug line. That is a quite a chunk of revenue for 3 years
So I guess that wasn't seen yet? Lookin' good!
I'm not sure if this was already posted. The intelgenx presentation was updated...
And the link...
http://intelgenx.com/investors/presentations.html
Sorry if someone already posted this.
MG